European Pharmaceutical Review

DECEMBER 20, 2023

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. The second is an adjustment of unmet need categorisation required for RDP extension; unmet need definition now encompasses ‘meaningful’ impact patient outcomes (notably including quality of life).

Biopharma 98

Biopharma Pharmaceutical Medicine Manufacturing 98

PM360

JUNE 16, 2023

In 2007, Alexion set a new pricing milestone of $500,000 annually for Soliris , a treatment for an ultra-rare blood disorder. As Payment Structures Change, Patient Access Must Evolve Rare diseases take the U.S. model of patient support and reimbursement hubs to new levels of white glove support.

Marketing 98

Marketing Management Insurance Specialization 98

Medico Reach

AUGUST 1, 2022

Whether you are a start-up looking for investment or are interested in working in venture capital (VC), the worldwide biopharma and MedTech industries are growing. In 2022, over $14 billion was funded in biopharma setup globally, and 37 major IPOs of VC-backed biotech company businesses raised a combined $4.2 CEO : Samuel Isaly.

Biopharma 52

Biopharma Healthcare Healthcare Medical 52

Clarivate

MAY 8, 2023

That was the overarching sentiment from the experienced group of biopharma leaders that formed the panel discussion chaired by Mike Ward, Clarivate Global Head of Life Sciences and Healthcare Thought Leadership, at this year’s AngloNordic Life Science conference. You have to be patiently impatient,” he said. Timing is everything.

Biopharma 52

Biopharma Sales Networking Pharma 52

Clarivate

APRIL 24, 2023

Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients. Key acquisitions by U.S. healthcare organizations Company Founded Type No.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

European Pharmaceutical Review

JULY 20, 2023

Dr Baghirzade continued, highlighting that since a particular defining moment for the industry in the late 90s, which resulted in an unfortunate patient fatality, “there is a lot more focus on safety” in gene therapy clinical trials today. She also touched on production costs being irrecoverable—there is a high cost per patient.

Consulting 74

Consulting Manufacturing Side effects Safety 74

PM360

NOVEMBER 12, 2024

We’re gaining a richer understanding of the brain’s complex inner workings, and today’s innovations reveal the vast, untapped potential of science and technology to transform the lives of patients and their families. Regarding leadership, my guiding principle has always been to do what’s right for patients and your people.

Food and Drug Administration 52

Food and Drug Administration Healthcare Provider Healthcare Healthcare 52